Evaluation of amentoflavone metabolites on PARP-1 inhibition and the potentiation on anti-proliferative effects of carboplatin in A549 cells

Wang, Baolin; Hu, Xiaolong; Wang, Rong; Liu, Huan

doi:10.1016/j.bmcl.2021.128480

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PARP1 inhibitors kill tumor cells after chemotherapy drugs have damaged the cell’s DNA by interfering with DNA damage repair. Chemotherapeutic drugs used in combination with PARP1 inhibitors mainly include alkylating agents, such as temozolomide ( 91 , 92 ) and melphalan ( 93 , 94 ); platinum-based drugs, such as cisplatin ( 95 ), carboplatin ( 96 ), and oxaliplatin ( 97 ); topoisomerase inhibitors, such as camptothecin ( 98 ) and irinotecan ( 99 ); anthracyclines, such as doxorubicin ( 100 ); antimetabolic chemotherapy drugs, such as gemcitabine ( 101 ); proteasome inhibitors, like bortezomib ( 102 ), and so on. Combined treatment generally benefits tumor control, and some combinations can effectively prolong the progression-free survival of cancer patients.…”

Section: Advances In Parp1 and Its Inhibitorsmentioning

confidence: 99%

Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization

Zhang,

Liang,

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Polyadenosine diphosphate-ribose polymerase (PARP) is a key modifying enzyme in cells, which participates in single-strand break repair and indirectly affects double-strand break repair. PARP inhibitors have shown great potential in oncotherapy by exploiting DNA damage repair pathways, and several small molecule PARP inhibitors have been approved by the U.S. Food and Drug Administration for treating various tumor types. PARP inhibitors not only have significant antitumor effects but also have some synergistic effects when combined with radiotherapy; therefore they have potential as radiation sensitizers. Here, we reviewed the advances and implications of PARP inhibitors in tumor radiotherapy sensitization. First, we summarized the multiple functions of PARP and the mechanisms by which its inhibitors exert antitumor effects. Next, we discuss the immunomodulatory effects of PARP and its inhibitors in tumors. Then, we described the theoretical basis of using PARP inhibitors in combination with radiotherapy and outlined their importance in oncological radiotherapy. Finally, we reviewed the current challenges in this field and elaborated on the future applications of PARP inhibitors as radiation sensitizers. A comprehensive understanding of the mechanism, optimal dosing, long-term safety, and identification of responsive biomarkers remain key challenges to integrating PARP inhibition into the radiotherapy management of cancer patients. Therefore, extensive research in these areas would facilitate the development of precision radiotherapy using PARP inhibitors to improve patient outcomes.

show abstract